DreamCIS Inc (223250) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DreamCIS Inc (223250) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.17 Billion ≈ $1.47 Million USD) by net assets (₩92.81 Billion ≈ $62.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DreamCIS Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how DreamCIS Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of DreamCIS Inc for a breakdown of total debt and financial obligations.
DreamCIS Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DreamCIS Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Graha Layar Prima Tbk
JK:BLTZ
|
0.257x |
|
Flexible Solutions International Inc
NYSE MKT:FSI
|
0.047x |
|
Syntec Construction Public Company Limited
BK:SYNTEC
|
-0.046x |
|
PP Presisi Tbk PT
JK:PPRE
|
-0.047x |
|
PT Janu Putra Sejahtera Tbk
JK:AYAM
|
0.017x |
|
Bhageria Industries Limited
NSE:BHAGERIA
|
0.049x |
|
DGL Group Ltd
AU:DGL
|
0.078x |
|
NWF GROUP PLC LS-25
F:NYY
|
N/A |
Annual Cash Flow Conversion Efficiency for DreamCIS Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of DreamCIS Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see how much is DreamCIS Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩67.96 Billion ≈ $46.06 Million |
₩-85.19 Million ≈ $-57.73K |
-0.001x | -100.97% |
| 2023-12-31 | ₩56.93 Billion ≈ $38.58 Million |
₩7.33 Billion ≈ $4.97 Million |
0.129x | -30.57% |
| 2022-12-31 | ₩48.96 Billion ≈ $33.18 Million |
₩9.08 Billion ≈ $6.16 Million |
0.186x | +19.79% |
| 2021-12-31 | ₩37.98 Billion ≈ $25.74 Million |
₩5.88 Billion ≈ $3.99 Million |
0.155x | +65.10% |
| 2020-12-31 | ₩36.46 Billion ≈ $24.71 Million |
₩3.42 Billion ≈ $2.32 Million |
0.094x | -76.46% |
| 2019-12-31 | ₩10.75 Billion ≈ $7.28 Million |
₩4.28 Billion ≈ $2.90 Million |
0.398x | -46.58% |
| 2018-12-31 | ₩6.51 Billion ≈ $4.41 Million |
₩4.85 Billion ≈ $3.29 Million |
0.746x | +27.42% |
| 2017-12-31 | ₩2.82 Billion ≈ $1.91 Million |
₩1.65 Billion ≈ $1.12 Million |
0.585x | -- |
About DreamCIS Inc
DreamCIS, Inc. operates as a clinical research organization in South Korea. It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headqua… Read more